When do the NORGESTREL AND ETHINYL ESTRADIOL patents expire, and when will NORGESTREL AND ETHINYL ESTRADIOL go generic?

Sponsor	Phase
Amgen	Phase 1
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 1
National Cancer Institute (NCI)	Phase 2

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mylan Labs Ltd	NORGESTREL AND ETHINYL ESTRADIOL	ethinyl estradiol; norgestrel	TABLET;ORAL-28	201828-001	Jun 21, 2016		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Mylan Labs Ltd	NORGESTREL AND ETHINYL ESTRADIOL	ethinyl estradiol; norgestrel	TABLET;ORAL-28	202875-001	May 8, 2017		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: September 26, 2026

Norgestrel and ethinyl estradiol is a mature combined oral contraceptive sold primarily through generic equivalents rather than a protected branded product. The market has low patent risk, limited manufacturer differentiation, and price-driven competition. Revenue is fragmented across low-cost prescription products, wholesalers, pharmacies, Medicaid programs, and health plans. The combination is unlikely to produce material branded-product growth unless a company creates a differentiated delivery system, prescription-to-OTC strategy, or specialty distribution channel.

What is norgestrel and ethinyl estradiol used for?

Norgestrel and ethinyl estradiol is a combined hormonal oral contraceptive containing an estrogen and a progestin. Common strengths include:

Product strength	Typical active ingredients
Standard low-dose combination	Norgestrel 0.30 mg and ethinyl estradiol 0.03 mg
Higher-dose combination	Norgestrel 0.50 mg and ethinyl estradiol 0.05 mg

Products have been marketed under names including Cryselle-28, Low-Ogestrel, Elinest, and Ogestrel, although product availability and manufacturer ownership have changed over time. The FDA-approved labeling describes the product as an oral contraceptive and includes the standard estrogen-related warnings concerning thromboembolic, cardiovascular, hepatic, and other risks.[1]

The combination competes with newer oral contraceptives containing levonorgestrel, desogestrel, norgestimate, drospirenone, or norethindrone. It also competes with long-acting reversible contraceptives, progestin-only pills, implants, injectables, intrauterine systems, condoms, and permanent contraception.

How large is the norgestrel and ethinyl estradiol market?

The precise revenue generated by norgestrel and ethinyl estradiol is not publicly disclosed as a standalone market category. The product is predominantly generic, and manufacturers generally report revenue at broader portfolio or segment levels.

The commercial market has four defining characteristics:

It is mature, with decades of clinical use and extensive generic substitution.
It has low average selling prices relative to branded contraceptives.
It is distributed through retail pharmacies, mail-order channels, Medicaid, commercial insurers, and cash-pay platforms.
Its demand is recurring but highly sensitive to payer reimbursement and pharmacy availability.

Prescription oral contraceptives remain a large U.S. pharmaceutical category, but the norgestrel/ethinyl estradiol segment represents a small share of that category. The principal economic value is in prescription volume and portfolio scale, not high revenue per prescription.

What drives demand?

Demand is supported by:

Continuing need for pregnancy prevention.
Stable use of oral contraceptives among reproductive-age patients.
Low generic prices.
Broad clinician familiarity.
Inclusion in public and private formularies.
Refill-based utilization.

Demand is constrained by:

Migration to long-acting reversible contraceptives.
Increased use of progestin-only options.
Patient concern about estrogen-related risks.
Substitution by newer combined oral contraceptives.
Contraceptive coverage disruptions caused by insurance or pharmacy changes.
Product discontinuations or temporary shortages among low-margin generic manufacturers.

What is the financial trajectory for norgestrel and ethinyl estradiol?

The financial trajectory is best characterized as stable volume with declining or flat nominal pricing.

Period	Market condition	Financial implication
1990s and earlier	Branded and early generic competition	Higher unit economics and greater brand value
2000s	Broad generic substitution	Lower prices and fragmented supply
2010s	Mature generic market	Volume stability with margin pressure
2020-2024	Consolidated generic procurement and changing contraceptive preferences	Low growth, intermittent supply risk, limited pricing power
Forward outlook	Continued generic use and channel competition	Stable demand but limited revenue expansion

A manufacturer entering the market is unlikely to obtain premium pricing solely from the active ingredients. Commercial upside would more likely come from:

A reliable supply agreement with a large pharmacy chain.
Medicaid or managed-care contracting.
A private-label arrangement.
A new dosage form or simplified packaging.
A digital-health or telehealth distribution model.
A contraceptive product portfolio that includes norgestrel/ethinyl estradiol alongside newer products.

Generic manufacturers typically face a cost structure dominated by active pharmaceutical ingredient procurement, quality testing, regulatory compliance, packaging, distribution, and retailer or wholesaler discounts. Because the formulation is established and substitutable, price increases can lead to rapid switching unless supply is constrained.

What patents protect norgestrel and ethinyl estradiol products?

No commercially material, unexpired composition-of-matter patent is associated with the established norgestrel and ethinyl estradiol combination. The underlying contraceptive technology predates the modern generic approval framework by decades.

The relevant intellectual-property position is therefore weak compared with newer pharmaceutical products:

IP category	Commercial position
Active-ingredient patents	Historical rights are expired
Combination-product patents	No known current blocking estate of material commercial significance
Formulation patents	Potentially relevant only if a manufacturer develops a differentiated formulation
Method-of-use patents	Limited value for established contraceptive use
Manufacturing patents	May protect process details but generally do not block standard generic manufacture
Trade secrets	Can protect process parameters, supplier relationships, and quality systems
Regulatory exclusivity	No meaningful current exclusivity barrier for the established generic combination

The FDA Orange Book remains the primary source for identifying listed patents and regulatory exclusivity for approved products.[2] For a mature generic contraceptive, the principal regulatory issues are usually abbreviated new drug application approval, bioequivalence, manufacturing compliance, and supply continuity rather than patent exclusion.

When does norgestrel and ethinyl estradiol lose exclusivity?

The combination lost practical market exclusivity long ago. Generic manufacturers can compete without waiting for a current branded patent term to expire, subject to FDA approval and applicable labeling requirements.

The relevant exclusivity analysis is:

Exclusivity type	Status
New chemical entity exclusivity	Expired
Original product patent protection	Expired or commercially irrelevant
Pediatric exclusivity	Not a current barrier
Orphan-drug exclusivity	Not applicable
Reference-product exclusivity	Not commercially significant for this mature product
Generic market exclusivity	Depends on the specific ANDA and any Paragraph IV filing, but no market-wide barrier is expected

The principal commercial risk is not loss of exclusivity. It is continued erosion of generic pricing and substitution among equivalent products.

What is the Orange Book status of norgestrel and ethinyl estradiol?

Products containing norgestrel and ethinyl estradiol have historically been approved as prescription oral contraceptives and have appeared in FDA product records under multiple applicants and product names. Orange Book status can change when an applicant discontinues a product, transfers an application, or updates its marketing status.

The key Orange Book implications are:

The reference products are old and no longer protected by a meaningful current patent estate.
Generic applicants generally rely on abbreviated approval pathways.
Product-specific patent listings should be reviewed by application number and strength.
A discontinued product may remain in FDA databases even when commercial supply has ended.
The presence of an Orange Book listing does not necessarily indicate active commercial sales.

The FDA’s Orange Book and Drugs@FDA databases provide the controlling regulatory records for product approval, therapeutic equivalence, patent listings, and marketing status.[2,3]

Are there Paragraph IV challenges for norgestrel and ethinyl estradiol?

Paragraph IV litigation is not a major current feature of the established norgestrel/ethinyl estradiol market. A Paragraph IV certification is commercially relevant when a generic applicant challenges an unexpired listed patent for a reference product. Because the key products are mature and genericized, the incentive to litigate is limited.

A new Paragraph IV dispute would be more plausible if a company obtained approval for:

A modified-release formulation.
A new delivery system.
A novel dosing schedule.
A product with a new indication.
A proprietary packaging or adherence technology.
A new fixed-dose combination with distinct clinical claims.

For standard immediate-release tablets, litigation risk is low. The larger risk is regulatory or supply disruption rather than patent injunction.

What formulation patents could protect future products?

A conventional tablet containing norgestrel and ethinyl estradiol has limited differentiation potential. A future applicant could seek protection for:

Modified-release formulations

A controlled-release tablet could seek patents covering release profiles, excipient combinations, particle size, or manufacturing processes. The commercial value would depend on demonstrated adherence, tolerability, or reduced dosing frequency.

Low-dose estrogen formulations

A lower ethinyl estradiol dose could support formulation and clinical-use claims if the product demonstrates a meaningful reduction in estrogen-related adverse effects without materially reducing contraceptive efficacy.

Transdermal or implantable delivery

A patch, implant, vaginal ring, or other delivery system could create a new product category. These technologies would face substantial development, pharmacokinetic, device, and regulatory requirements.

Patient-specific packaging

Calendar packs, digital reminders, and adherence systems can be protected through a combination of device, software, and packaging rights. Those rights would protect the delivery experience rather than the underlying active ingredients.

Manufacturing methods

Process patents may cover crystallization, granulation, coating, impurity control, or tablet compression. Such patents can increase manufacturing barriers but usually do not prevent competitors from using alternative processes.

Which companies are competing in the market?

Competition is fragmented among generic pharmaceutical manufacturers, contract manufacturers, wholesalers, retail pharmacies, and private-label suppliers. Manufacturers associated with oral contraceptive generics have included large and mid-sized companies such as Amneal, Glenmark, Lupin, Mayne Pharma, Teva, Viatris, and other approved applicants, depending on product, strength, and period.

The commercial landscape changes frequently because generic companies:

Exit products with low margins.
Transfer marketing applications.
Reduce manufacturing capacity.
Consolidate portfolios.
Enter supply agreements with pharmacy chains.
Prioritize higher-volume or higher-margin medicines.

The relevant competitive metric is not brand recognition. It is reliable availability at a reimbursable price.

What is the FDA regulatory status?

Norgestrel and ethinyl estradiol products are prescription combined oral contraceptives approved under established FDA pathways. Generic products must demonstrate pharmaceutical equivalence and bioequivalence to the relevant reference product under an ANDA or other applicable pathway.[3]

The main regulatory requirements include:

Conformance with approved strength and dosage form.
Bioequivalence.
Manufacturing under current good manufacturing practices.
Stability and packaging compliance.
Accurate labeling.
Pharmacovigilance and adverse-event reporting.
Continued commercial reporting to the FDA.

The FDA authorized Opill, a norgestrel-only oral contraceptive, for nonprescription use in 2023. Opill does not contain ethinyl estradiol and is not a substitute for the norgestrel/ethinyl estradiol combination from a formulation or regulatory perspective.[4] Its authorization may expand consumer awareness of norgestrel as a contraceptive ingredient, but it also creates a separate competitive pathway for progestin-only contraception.

Does biosimilar risk affect norgestrel and ethinyl estradiol?

No. Biosimilar risk is not relevant because norgestrel and ethinyl estradiol are chemically synthesized small molecules, not biologic products. The applicable competitive threat is generic substitution, not biosimilar competition.

The market therefore lacks the biologic-specific barriers associated with cell-line development, analytical comparability, interchangeability designations, and complex manufacturing validation.

What patent litigation affects the product?

No major current patent litigation is central to the commercial market for standard norgestrel and ethinyl estradiol tablets. The mature generic status of the combination reduces the expected value of infringement litigation.

Potential disputes would more likely concern:

ANDA approval and product labeling.
Manufacturing or quality failures.
Supply contracts.
Trademark rights.
Packaging or trade dress.
A newly patented formulation.
Product liability claims unrelated to exclusivity.

For investors and licensors, litigation exposure is therefore lower than for recently launched branded drugs, but product liability and regulatory-compliance exposure remain relevant for estrogen-containing contraceptives.

How does norgestrel and ethinyl estradiol compare with competing contraceptives?

Product category	Patent strength	Price level	Growth outlook	Main commercial advantage
Norgestrel/ethinyl estradiol generic tablets	Low	Low	Flat to declining	Established, inexpensive oral option
Newer branded combined pills	Medium to high	Medium to high	Selective growth	Differentiated tolerability, branding, or dosing
Progestin-only pills	Variable	Low to medium	Growing	Estrogen-free positioning
Long-acting reversible contraceptives	High for some products	High gross value	Stronger growth	Duration and adherence
Transdermal systems and vaginal rings	Medium to high	Medium to high	Selective	Alternative delivery
OTC norgestrel-only Opill	Product-specific	Consumer cash-pay dependent	Potential category expansion	Nonprescription access

Norgestrel/ethinyl estradiol remains competitive when patients prioritize low cost, oral administration, familiarity, and broad generic availability. It is less competitive when patients seek estrogen-free contraception, long-acting protection, or a newer delivery system.

What generic launch scenarios exist?

Base case

Generic supply remains available, with modest prescription volume and continued price erosion. Manufacturers maintain the product as part of a broader contraceptive portfolio rather than as a standalone growth asset.

Upside case

A company creates a differentiated formulation, secures preferred formulary status, or distributes the product through a large telehealth or pharmacy network. Revenue rises through volume and channel control rather than patent pricing.

Downside case

Manufacturers exit because of low margins, raw-material constraints, quality issues, or reduced demand. Temporary shortages support short-term price increases, but the long-term market remains generic and competitive.

Strategic-licensing case

A licensee combines the active ingredients with adherence software, calendar packaging, a new delivery system, or a broader women’s-health platform. The value would arise from the platform and distribution rights, not from the old active-ingredient combination.

What geographic markets matter?

The combination has been marketed internationally under different brand names, strengths, and regulatory classifications. Geographic value depends on:

National reimbursement.
Local generic registration rules.
Tender procurement.
Contraceptive access policies.
Pharmacy distribution.
Local manufacturing requirements.
Currency and price controls.

The United States is commercially important because of its large prescription market and established generic approval framework. Emerging markets may offer greater unit growth but often produce lower net prices and higher regulatory or distribution complexity.

Key Takeaways

Norgestrel and ethinyl estradiol is a mature generic contraceptive combination.
The active ingredients have no meaningful remaining composition-of-matter exclusivity.
Current revenue is fragmented and not generally reported as a standalone public segment.
The financial outlook is stable volume with limited pricing power and declining generic margins.
Patent litigation and Paragraph IV risk are low for standard immediate-release tablets.
The relevant competitive threat is generic substitution and migration to newer contraceptive methods.
Biosimilar risk does not apply.
Commercial upside would require formulation innovation, OTC or digital distribution, preferred contracting, or portfolio integration.
Opill expands norgestrel visibility but is a progestin-only product and does not contain ethinyl estradiol.
Supply reliability, reimbursement access, and manufacturing economics matter more than patent strength.

FAQs

Is norgestrel and ethinyl estradiol still commercially available?

Availability depends on product, strength, manufacturer, and pharmacy inventory. Products may appear under several generic or legacy brand names, and individual manufacturers can discontinue or transfer marketing applications.

Is norgestrel and ethinyl estradiol the same as Opill?

No. Opill contains norgestrel alone and does not contain ethinyl estradiol. It is a progestin-only oral contraceptive authorized for nonprescription use in the United States.[4]

Can a company obtain a new patent on norgestrel and ethinyl estradiol?

A company generally cannot obtain a new composition patent on an old active-ingredient combination. It may seek patents on a novel formulation, delivery system, manufacturing process, packaging system, or clinically differentiated use.

Is norgestrel and ethinyl estradiol a high-margin pharmaceutical product?

Generally no. Generic price competition, substitution, and payer contracting limit margins. Profitability depends on manufacturing efficiency, supply reliability, scale, and distribution agreements.

What would increase the market value of this contraceptive combination?

The strongest value drivers would be a differentiated delivery system, improved adherence, new regulatory status, preferred payer access, OTC distribution, or integration into a broader women’s-health platform.

References

U.S. Food and Drug Administration. (n.d.). Cryselle-28 prescribing information. FDA.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA.
U.S. Food and Drug Administration. (n.d.). Drugs@FDA and abbreviated new drug application resources. FDA.
U.S. Food and Drug Administration. (2023). FDA approves first nonprescription daily oral contraceptive. FDA.

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	9
Clinical Trials:	5
Patent Applications:	684
DailyMed Link:	NORGESTREL AND ETHINYL ESTRADIOL at DailyMed

AI Deep Research

Questions you can ask:

Summary for NORGESTREL AND ETHINYL ESTRADIOL

Recent Clinical Trials for NORGESTREL AND ETHINYL ESTRADIOL